Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease
An early and accurate diagnosis of Alzheimer's disease (AD) is required to initiate symptomatic treatment with currently approved drugs and will be of even greater importance if disease modifying compounds in development display a clinical effect. Protein profiles of human cerebrospinal fluid samples from AD patients (n = 95) and population-based healthy controls (n = 72) were analyzed by SELDI-TO